论文部分内容阅读
目的:探讨瑞舒伐他汀对高胆固醇血症患者颈动脉内膜中层厚度及血管内皮功能的影响。方法:入选110例高胆固醇血症患者,随机分成瑞舒伐他汀治疗组36例、阿托伐他汀治疗组38例和饮食治疗组36例;入选30例健康者作为正常对照组。给予瑞舒伐他汀、阿托伐他汀治疗及饮食治疗8周,治疗前及治疗后分别检测颈动脉内膜中层厚度(IMT)及肱动脉血管内皮依赖性舒张功能(EDFMD)及血脂等。结果:与正常对照组相比,瑞舒伐他汀治疗组、阿托伐他汀治疗组和饮食治疗组IMT显著高于正常对照组(P<0.05),而EDFMD显著低于正常对照组(P<0.05)。与治疗前相比,瑞舒伐他汀治疗组和阿托伐他汀治疗组治疗8周后IMT显著降低(P均<0.05),而EDFMD显著升高(P均<0.05)。饮食治疗组治疗8周后IMT和EDFMD差异无显著性(P>0.05)。结论:瑞舒伐他汀与阿托伐他汀一样具有抗动脉粥样硬化和改善血管内皮功能作用,能够显著升高EDFMD,而显著降低IMT,可能是其改善心血管疾病预后的重要机制之一。
Objective: To investigate the effect of rosuvastatin on carotid artery intima-media thickness and endothelial function in patients with hypercholesterolemia. Methods: A total of 110 patients with hypercholesterolemia were randomly divided into rosuvastatin treatment group (36 cases), atorvastatin treatment group (38 cases) and dietary therapy group (36 cases). 30 healthy subjects were selected as normal control group. The patients were given rosuvastatin and atorvastatin for 8 weeks. The carotid intima-media thickness (IMT), brachial artery endothelium-dependent vasodilatation (EDFMD) and blood lipids were measured before and after treatment. Results: Compared with the normal control group, the IMT in the rosuvastatin group, the atorvastatin group and the dietary treatment group were significantly higher than those in the normal control group (P <0.05), while the EDFMD was significantly lower than that in the normal control group (P < 0.05). IMT decreased significantly (P <0.05) and EDFMD increased significantly (P <0.05) in both rosuvastatin and atorvastatin groups compared with those before treatment. There was no significant difference in IMT and EDFMD between the dietary treatment group and the 8-week treatment group (P> 0.05). Conclusion: Rosuvastatin, as atorvastatin, has anti-atherosclerosis and vascular endothelial function. It can significantly increase EDFMD and decrease IMT significantly, which may be one of the important mechanisms to improve the prognosis of cardiovascular diseases.